Table 1.

Demographic and clinical information of the studied subjects^A

Demographics			Clinical measures				Serology			Other
Subject	Age (yr)	RaceB	FSC	WUSFD	vBjstE	SchirF	RoG	LaH	RFI	EGMJ	EGCK
1	48	EA/AI	1.3/+	4.786/−	4/+	13/−	−	−	−	−	Ind
2	51	EA	9/+	3.799/−	6/+	2/+	+	+	+	+	−
3	35	EA	4/+	11.774/−	8/+	22/−	−	−	−	+	+
4	35	EA	5.7/+	3.158/−	4/+	14/−	+	−	+	+	−
5	58	EA	12/+	0.030/+	9/+	2/+	+	+	+	+	+
6	43	EA/AI	1.8/+	2.819/−	4/+	25/−	−	−	−	−	Ind
7	49	EA	2/+	1.879/−	6/+	9/−	+	−	−	−	−
8	60	EA	3/+	3.182/−	4/+	25/−	+	−	+	+	+
9	69	EA/AI	4.6/+	0.631/+	3/−	8/−	−	+	−	−	+
10	30	EA/AI	4/+	0.001/+	9/+	1/+	+	+	+	+	Ind

^AAll participants were women reporting symptoms of dry eyes and dry mouth and fulfilling both the American-European Consensus Group and American College of Rheumatology criteria for pSS. “+” indicates a positive test for the indicated parameter. “−” indicates a negative test for the indicated parameter. Disease duration (diagnosis or classification) was less than or equal to 1 year for all participants except subject 5, who had a disease duration of 11 years.

^BEA, self-reported European American descent; EA/AI, self-reported mixed European American/American Indian descent.

^CFS, focus score.

^DWUSF, whole unstimulated salivary flow (ml/15 min).

^EvBjst, van Bijsterveld ocular surface staining score, highest value (most abnormal) eye.

^FSchirmer’s tear flow (mm/5 min), lowest value (most abnormal) eye.

^GRo (+): positive antibody test at clinic visit or in medical record.

^HLa (+): positive antibody test at clinic visit or in medical record.

^IRF, rheumatoid factor.

^JEGM, extraglandular manifestation of one or more of the following: hypergammaglobulinemia, Raynaud’s phenomenon, peripheral neuropathy, elevated erythrocyte sedimentation rate, arthritis (synovitis), leukopenia, or hypocomplementemia.

^KEGC, ectopic germinal center-like structure in SG. Ind, indeterminate.